Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
作者信息
Matulis Shannon M, Gupta Vikas A, Neri Paola, Bahlis Nizar J, Maciag Paulo, Leverson Joel D, Heffner Leonard T, Lonial Sagar, Nooka Ajay K, Kaufman Jonathan L, Boise Lawrence H
机构信息
Department of Hematology and Medical Oncology, Emory University School of Medicine and the Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.
出版信息
Leukemia. 2019 May;33(5):1291-1296. doi: 10.1038/s41375-018-0374-8. Epub 2019 Jan 24.
Abstract
摘要
相似文献
1
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.维奈托克敏感性的功能分析可预测多发性骨髓瘤的临床反应。
Leukemia. 2019 May;33(5):1291-1296. doi: 10.1038/s41375-018-0374-8. Epub 2019 Jan 24.
2
Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.用一例对维奈托克敏感的难治性疾病解释多发性骨髓瘤中t(11;14)的生物学意义
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):e556-e559. doi: 10.1016/j.clml.2020.05.028. Epub 2020 Jun 14.
3
BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma.BH3分析作为一种识别多发性骨髓瘤对维奈托克获得性耐药的工具。
Br J Haematol. 2017 Nov;179(4):684-688. doi: 10.1111/bjh.14251. Epub 2016 Jul 29.
4
Targeting Bcl-2 for the treatment of multiple myeloma.针对 Bcl-2 治疗多发性骨髓瘤。
Leukemia. 2018 Sep;32(9):1899-1907. doi: 10.1038/s41375-018-0223-9. Epub 2018 Aug 3.
5
Venetoclax in a Patient With Light Chain Deposition Disease Secondary to MGRS That Progressed After Kidney Transplantation.维奈克拉治疗一名肾移植后进展的MGRS继发轻链沉积病患者。
Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):e488-e491. doi: 10.1016/j.clml.2020.03.013. Epub 2020 Apr 7.
6
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.接受维奈托克单药治疗的慢性淋巴细胞白血病患者凋亡机制中复发性基因组改变的鉴定
Am J Hematol. 2022 Feb 1;97(2):E47-E51. doi: 10.1002/ajh.26411. Epub 2021 Nov 24.
7
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.基质介导的多发性骨髓瘤中 miR-193b-3p 和 miR-21-5p 失调诱导的 MCL-1 和 BCL-2 表达变化导致 S63845 和 Venetoclax 耐药。
Cells. 2021 Mar 4;10(3):559. doi: 10.3390/cells10030559.
8
Secondary plasma cell leukaemia treated with single agent venetoclax.采用单药维奈克拉治疗继发性浆细胞白血病。
Br J Haematol. 2020 Aug;190(4):e242-e245. doi: 10.1111/bjh.16858. Epub 2020 Jun 11.
9
Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).在一名患有非常晚期难治性骨髓瘤且伴有t(11;14)易位的患者中，维奈克拉治疗后出现深度且持续的缓解。
Haematologica. 2017 Mar;102(3):e112-e114. doi: 10.3324/haematol.2016.160408. Epub 2017 Jan 5.
10
Venetoclax for the treatment of multiple myeloma.维奈托克治疗多发性骨髓瘤。
Expert Rev Hematol. 2018 Dec;11(12):915-920. doi: 10.1080/17474086.2018.1548931. Epub 2018 Dec 6.
引用本文的文献
1
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma.多发性骨髓瘤中维奈托克反应的预测因素及CDK7抑制的治疗潜力
Blood Neoplasia. 2024 Oct 14;1(4):100049. doi: 10.1016/j.bneo.2024.100049. eCollection 2024 Dec.
2
Estimating treatment sensitivity in synthetic and in vitro tumors using a random differential equation model.使用随机微分方程模型估计合成肿瘤和体外肿瘤的治疗敏感性。
NPJ Syst Biol Appl. 2025 May 23;11(1):54. doi: 10.1038/s41540-025-00530-0.
3
VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target.电压依赖性阴离子通道2（VDAC2）使骨髓瘤细胞对依赖BAK的凋亡敏感，是一个新的治疗靶点。
Leukemia. 2025 Apr;39(4):995-1000. doi: 10.1038/s41375-025-02523-8. Epub 2025 Feb 6.
4
Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients.新诊断多发性骨髓瘤患者中Bcl-2家族蛋白的表达谱
Hemasphere. 2024 Dec 13;8(12):e70036. doi: 10.1002/hem3.70036. eCollection 2024 Dec.
5
Flow cytometric expression of Bcl-2, Mcl-1, and their ratios correlates with primary and secondary cytogenetic changes and their combinations in multiple myeloma.Bcl-2、Mcl-1的流式细胞术表达及其比率与多发性骨髓瘤的原发性和继发性细胞遗传学改变及其组合相关。
Ann Hematol. 2024 Dec;103(12):5473-5481. doi: 10.1007/s00277-024-06004-3. Epub 2024 Sep 12.
6
Profiling protein-protein interactions to predict the efficacy of B-cell-lymphoma-2-homology-3 mimetics for acute myeloid leukaemia.分析蛋白质-蛋白质相互作用，预测 B 细胞淋巴瘤-2 同源物-3 模拟物对急性髓系白血病的疗效。
Nat Biomed Eng. 2024 Nov;8(11):1379-1395. doi: 10.1038/s41551-024-01241-3. Epub 2024 Jul 18.
7
Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma.5-氮杂胞苷和维奈托克联合无类固醇治疗多发性骨髓瘤。
Haematologica. 2024 Sep 1;109(9):2930-2943. doi: 10.3324/haematol.2023.283771.
8
Using birth-death processes to infer tumor subpopulation structure from live-cell imaging drug screening data.利用生死过程从活细胞成像药物筛选数据推断肿瘤亚群结构。
PLoS Comput Biol. 2024 Mar 6;20(3):e1011888. doi: 10.1371/journal.pcbi.1011888. eCollection 2024 Mar.
9
The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma.t(11;14)在多发性骨髓瘤治疗决策制定中的作用
Cancers (Basel). 2023 Dec 13;15(24):5829. doi: 10.3390/cancers15245829.
10
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).伴有 t(6;14)易位的复发/难治性多发性骨髓瘤患者中有效的维奈托克治疗。
Pathol Oncol Res. 2023 Nov 10;29:1611375. doi: 10.3389/pore.2023.1611375. eCollection 2023.
Zotero 插件